API Products

Celadon’s 100,000 sq ft UK facility is licenced by UK regulators to cultivate high-THC cannabis and by MHRA to manufacture cannabinoid API’s.

GMP Cannabis API

Flower API

Celadon uses indoor hydroponic cultivation systems in a fully controlled environment, designed to cultivate the highest-industry standard of GMP cannabis flower.

Oil API

Celadon has a certified GMP extraction room and can produce a variety of bulk GMP cannabis oils to meet customer specific requirements.

Celadon RX11 Cannabis Flower

CEL-F15/0

GENETICS: RX11

CEL-F15/0 is a meticulously bred cannabis strain deriving from RX11 genetics. Utilising a pool of genetics, Celadon has identified an exceptional phenotype showcasing the most desirable traits from a number of parent strains. This strain is cultivated to GMP pharmaceutical grade standards, ensuring consistent quality and stability.

CEL-F20/0

GENETICS: Zerberry

CEL-F20/0 is a meticulously bred cannabis strain deriving from Zerberry genetics. Utilising a pool of genetics, Celadon has identified an exceptional phenotype showcasing the most desirable traits from a number of parent strains. This strain is cultivated to GMP pharmaceutical grade standards, ensuring consistent quality and stability.

Celadon Zerberry Cannabis Flower
Celadon Ozark Cannabis Flower

CEL-F19/0

GENETICS: OZARK

CEL-F19/0 is meticulously bred cannabis strain deriving from Ozark genetics. Utilising a unique pool of genetics, Celadon has bred an exceptional phenotyre showcasing the most desirable traits from a number of parent strains. This strain is cultivated to GMP pharmaceutical grade standards, ensuring consistent quality and stability.

Cannabis Oil API

Celadon Pharmaceuticals is at the forefront of innovation, offering bespoke API oils meticulously extracted from cannabis plants. Our state-of-the-art facilities and rigorous extraction processes ensure the highest quality and purity of these oils.

Furthermore, Celadon is dedicated to developing its own formulations, specifically targeting a range of medical conditions. These proprietary formulations are designed with precision to meet the therapeutic needs of patients for eventual licensing as approved medicines.

Celadon Cannabis API Oil

Licenced by the MHRA

Celadon Pharmaceuticals is proud to be licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) to provide and distribute a variety of Active Pharmaceutical Ingredients (APIs) produced under strict Good Manufacturing Standards (GMP). This prestigious accreditation underscores our commitment to maintaining the highest standards in pharmaceutical manufacturing and distribution.

What is an API?

An Active Pharmaceutical Ingredient (API) is the component of a medication that produces the intended therapeutic effects. APIs are critical in ensuring the efficacy and safety of pharmaceuticals, as they are responsible for the drug’s action in the body. The production of high-quality APIs is essential in the development of effective medications, and at Celadon, we adhere to stringent quality control measures to guarantee that our APIs meet rigorous regulatory standards.

Our current portfolio of APIs includes the following:

CANNABIS FLOWER

CANNABICHROMENE

CANNABIDIOL

CANNABIDIVARIN

CANNABIGEROL

CANNABINOL

TETRAHYDROCANNABIVARIN

CANNABIS BULK

CANNABICHROMENIC ACID

CANNABIDIOLIC ACID

CANNABIDIVARINIC ACID

CANNABIGEROLIC ACID

TETRAHYDROCANNABIVARINIC ACID

TETRAHYDROCANNABINOLIC ACID

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Medical Cannabis Market, Transparency Market Research May 2022

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Legalised in 2018

This will close in 0 seconds

Legalised in 37 States Limited Federal legalisation

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016 Rapid growth to >200k patients (2019-21)

This will close in 0 seconds

Legalised in 2001

This will close in 0 seconds

BUSINESS DESCRIPTION

 

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism.

Its 100,000 sq ft UK facility operates to an EU-GMP standard and comprises indoor hydronic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company’s subsidiary owns a Medicines and Healthcare Products Regulatory Agency (“MHRA”) approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics Limited which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder

This will close in 0 seconds

COUNTRY OF INCORPORATION/OPERATION

 

Celadon Pharmaceuticals Plc is incorporated in England and Wales and is listed solely on the London Stock
Exchange Alternative Investment Market (AIM), and is subject to the UK City Code on Takeovers and Mergers.

TIDM: CEL.L
ISIN: GB00BDQYGP38

There are no restrictions on the transfer of Celadon Pharmaceutical’s shares.

This will close in 0 seconds

AIM SECURITIES IN ISSUE

 

The following information is correct as at 7th March 2025.

The Company’s issued share capital comprises

68,845,807 ordinary shares

Each with a nominal value of 1 pence

So far as the Company is aware, 41.71% of its issued share capital is not in public hands.

This will close in 0 seconds

Scroll to Top